Abstract
Aminopeptidase N (APN) is a ubiquitous enzyme overexpressed on tumor cells and plays an important role in angiogenesis and metastasis of tumor. Bestatin as an effective inhibitor of aminopeptidase N is used for complementary treatment of cancer with other drugs. In this work, we reformed the structure of bestatin to a new derivative LYP3 to improve the water solubility and effectiveness. The inhibitory activity of LYP3 against APN was evaluated in vitro.
Keywords: Aminopeptidase N, bestatin, tumorigenesis, A549, ES-2, MDA-MB-231, tumor cells, angiogenesis, metastasis of tumor, met-alloprotease, angiotensin, enkephalin, neovascularization, leukemia, pharmacokinetics, biotransformation, L-serine benzylamine, flash chromatography, acylation, recrystallization, Water Solubility Assay, Lambert-Beer law, APN Inhibition Assay, L-leucine-p-nitroanilide, microsomal amino-peptidase, MMP-2 Inhibition Assay, ma-trix metalloproteinase-2 (MMP-2), MTT Assay, fetal bovine serum, diphenyltetrazolium bromide, mono-hydrochloride salt, APN high-expressed tumor cell line, APN low-expressed tumor cell line, immunostimulating effect
Medicinal Chemistry
Title: LYP3, a New Bestatin Derivative for Aminopeptidase N Inhibition
Volume: 7 Issue: 1
Author(s): Yepeng Luan, Chunhua Ma, Zhongguo Sui, Xuejian Wang, Jinhong Feng, Ning Liu, Fanbo Jing, Yan Wang, Minyong Li, Hao Fang and Wenfang Xu
Affiliation:
Keywords: Aminopeptidase N, bestatin, tumorigenesis, A549, ES-2, MDA-MB-231, tumor cells, angiogenesis, metastasis of tumor, met-alloprotease, angiotensin, enkephalin, neovascularization, leukemia, pharmacokinetics, biotransformation, L-serine benzylamine, flash chromatography, acylation, recrystallization, Water Solubility Assay, Lambert-Beer law, APN Inhibition Assay, L-leucine-p-nitroanilide, microsomal amino-peptidase, MMP-2 Inhibition Assay, ma-trix metalloproteinase-2 (MMP-2), MTT Assay, fetal bovine serum, diphenyltetrazolium bromide, mono-hydrochloride salt, APN high-expressed tumor cell line, APN low-expressed tumor cell line, immunostimulating effect
Abstract: Aminopeptidase N (APN) is a ubiquitous enzyme overexpressed on tumor cells and plays an important role in angiogenesis and metastasis of tumor. Bestatin as an effective inhibitor of aminopeptidase N is used for complementary treatment of cancer with other drugs. In this work, we reformed the structure of bestatin to a new derivative LYP3 to improve the water solubility and effectiveness. The inhibitory activity of LYP3 against APN was evaluated in vitro.
Export Options
About this article
Cite this article as:
Luan Yepeng, Ma Chunhua, Sui Zhongguo, Wang Xuejian, Feng Jinhong, Liu Ning, Jing Fanbo, Wang Yan, Li Minyong, Fang Hao and Xu Wenfang, LYP3, a New Bestatin Derivative for Aminopeptidase N Inhibition, Medicinal Chemistry 2011; 7 (1) . https://dx.doi.org/10.2174/157340611794072706
DOI https://dx.doi.org/10.2174/157340611794072706 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Cigarette Smoke-mediated Perturbations of the Immune Response: A New Therapeutic Approach with Natural Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Mast Cell Development by Inflammatory Factors
Current Medicinal Chemistry Dietary Fish Oil Concentrates Associated Health Benefits: A Recent Development of Cardiovascular Risk Reduction
Current Pharmaceutical Design Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Heat Shock Protein Gp96 as Potential Regulator of Morphostasis after Partial Hepatectomy in Mice
Current Aging Science Genetics in Osteoarthritis
Current Genomics Behavioral Experimental Paradigms for the Evaluation of Drug’s Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory
CNS & Neurological Disorders - Drug Targets Clinical Profile and Risk Factors of Central Serous Chorioretinopathy in Al- Ain, United Arab Emirates
New Emirates Medical Journal Needle-free Gene Delivery Through the Skin: An Overview of Recent Strategies
Current Pharmaceutical Design The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Targeting Leukostasis for the Treatment of Early Diabetic Retinopathy
Cardiovascular & Hematological Disorders-Drug Targets Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Gallic Acid Protects from Acute Multiorgan Injury Induced by Lipopolysaccharide and D-galactosamine
Current Pharmaceutical Biotechnology Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hydrogen Sulphide and Pain
Inflammation & Allergy - Drug Targets (Discontinued) The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
Current Drug Targets - Infectious Disorders Other Activities
Current Bioactive Compounds